Cardiovascular risks of anemia correction with erythrocyte stimulating agents: Should blood viscosity be monitored for risk assessment?

Keyphrases

• Cardiovascular Risk 100%
• Risk Assessment 100%
• Erythrocytes 100%
• Blood Viscosity 100%
• Stimulating Agent 100%
• Anemia Correction 100%
• Cardiovascular Disease 50%
• Cardiovascular Events 50%
• Improved Outcomes 25%
• Clinical Trials 25%
• Myocardial Infarction 25%
• Hemoglobin 25%
• Angina 25%
• Postmenopausal Women 25%
• Heart Failure 25%
• Coronary Artery Bypass Grafting 25%
• Erythropoietin 25%
• Percutaneous Transluminal Coronary Angioplasty 25%
• Strong Predictor 25%
• Non-donors 25%
• Thrombotic 25%
• Menstruation 25%
• Blood Donors 25%
• Atherothrombosis 25%
• Viscosity 25%
• Cardiovascular Risk Assessment 25%
• Vascular Thrombosis 25%
• Blood Donation 25%
• Whole Blood Viscosity 25%
• Menopausal Age 25%
• Pathophysiological Factors 25%
• Risk Management Practices 25%
• Event Failure 25%
• Viscosity Monitoring 25%

Medicine and Dentistry

• Anemia 100%
• Cardiovascular Disease 100%
• Analeptic 100%
• Cardiovascular Risk 100%
• Erythrocyte 100%
• Apoplexy 66%
• Cardiovascular System 66%
• Thrombosis 66%
• Blood Donor 66%
• Clinical Trial 33%
• Congestive Heart Failure 33%
• Myocardial Infarction 33%
• Angina pectoris 33%
• Postmenopause 33%
• Coronary Artery Bypass Graft 33%
• Transluminal Coronary Angioplasty 33%
• Erythropoietin 33%

Pharmacology, Toxicology and Pharmaceutical Science

• Anemia 100%
• Cardiovascular Risk 100%
• Cardiovascular Disease 100%
• Thrombosis 66%
• Cerebrovascular Accident 66%
• Heart Infarction 33%
• Congestive Heart Failure 33%
• Clinical Trial 33%
• Erythropoietin 33%